Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Pliant Therapeutics (PLRX) Return on Capital Employed (2020 - 2026)

Pliant Therapeutics has reported Return on Capital Employed over the past 7 years, most recently at 58.56% for Q1 2026.

  • Quarterly Return on Capital Employed rose 999.0% to 58.56% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 58.56% through Mar 2026, up 999.0% year-over-year, with the annual reading at 53.06% for FY2025, 114.0% up from the prior year.
  • Return on Capital Employed was 58.56% for Q1 2026 at Pliant Therapeutics, up from 66.67% in the prior quarter.
  • Over five years, Return on Capital Employed peaked at 28.51% in Q2 2023 and troughed at 72.87% in Q2 2025.
  • The 5-year median for Return on Capital Employed is 52.29% (2024), against an average of 50.68%.
  • Year-over-year, Return on Capital Employed crashed -3310bps in 2022 and then soared 3660bps in 2023.
  • A 5-year view of Return on Capital Employed shows it stood at 37.41% in 2022, then rose by 1bps to 36.99% in 2023, then crashed by -59bps to 58.84% in 2024, then dropped by -13bps to 66.67% in 2025, then increased by 12bps to 58.56% in 2026.
  • Per Business Quant, the three most recent readings for PLRX's Return on Capital Employed are 58.56% (Q1 2026), 66.67% (Q4 2025), and 68.78% (Q3 2025).